Multiple Pathologies Clinical Trial
— GREATOfficial title:
'GREAT' Global Registry for Endovascular Aortic Treatment - Outcomes Evaluation
| Verified date | May 2024 |
| Source | W.L.Gore & Associates |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational [Patient Registry] |
Prospective, observational Registry to obtain data on device performance and clinical outcomes.
| Status | Active, not recruiting |
| Enrollment | 4600 |
| Est. completion date | June 2027 |
| Est. primary completion date | June 2027 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility | Inclusion Criteria: - Minimum age required by state regulations - Indication for aortic endovascular stent graft repair - Signed informed consent Exclusion Criteria: - N/A |
| Country | Name | City | State |
|---|---|---|---|
| Australia | Royal Prince Alfred Hospital | Camperdown | New South Wales |
| Brazil | Coris Medicina Avançada | Florianópolis | |
| Italy | Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico | Milano | |
| Italy | IRCCS Policlinico San Donato | Milano | |
| United States | The University of Chicago Medicine & Biological Sciences | Chicago | Illinois |
| United States | Baylor Research Institute | Plano | Texas |
| Lead Sponsor | Collaborator |
|---|---|
| W.L.Gore & Associates |
United States, Australia, Brazil, Italy,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | To collect "real world" data on the incidence of serious device events. | Up to 10 years |